Drug Details
| General Information of the Drug (ID: DR3943) | ||||
|---|---|---|---|---|
| Name |
Carboplatin
|
|||
| Synonyms |
Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Ovarian cancer [ICD-11: 2C73] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 27.18 +/- 11.28 mgh/L
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 9.06 +/- 0.74 mg/L
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Clearance
The total body clearance of drug is 4.4 L/h
Elimination
Carboplatin is 65% eliminated in the urine within 12 hours, and 71% eliminated within 24 hours
Half-life
The concentration or amount of drug in body reduced by one-half in 1.1 - 2 hours
Metabolism
The drug is not metabolised
Unbound Fraction
The unbound fraction of drug in plasma is 1%
Vd
The volume of distribution (Vd) of drug is 16 L
Water Solubility
The ability of drug to dissolve in water is measured as 14 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C6H12N2O4Pt
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
|
|||
| InChI |
1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2
|
|||
| InChIKey |
VSRXQHXAPYXROS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 41575-94-4
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Celastrol | Celastrus strigillosus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Induction | Degradation | FANCD2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HSJD-DIPG-07 | CVCL_VU70 | Diffuse intrinsic pontine glioma | Homo sapiens | ||
| JHH-DIPG-1 | CVCL_IT47 | Diffuse intrinsic pontine glioma | Homo sapiens | |||
| SU-DIPG-IV | CVCL_IT39 | Diffuse intrinsic pontine glioma | Homo sapiens | |||
| SU-pcGBM-2 | CVCL_IT42 | Glioblastoma | Homo sapiens | |||
| VUMC-DIPG-10 | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-DIPG-F | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-DIPG-G | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-HGG-09 | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-HGG-14 | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-HGG-11 | Pediatric high-grade gliomas | Homo sapiens | ||||
| In-vivo Model | VUMC-HGG-14 cells (50*104 cells in 5 uL) were stereotactically injected into the striatum (4-week old female athymic nude mice). | |||||
| Experimental
Result(s) |
Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. | |||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity. | |||||
| Vanadium | Vanadinite | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Induction | Cell cycle arrest in G0/G1 phase | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| MDA-231 | Breast cancer | Homo sapiens | ||||
| Experimental
Result(s) |
Combination of vanadium and carboplatin resulted in synergistic antitumor activity in ex vivo cell cultures, and prompted G0/G1 cell cycle arrest and sensitization of tumor cells to carboplatin-induced apoptosis. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Collagen alpha-1 I (COL1A1) | Molecule Info | ||
| Eukaryotic translation initiation factor 2A (EIF2A) | Molecule Info | |||
| Human Deoxyribonucleic acid (hDNA) | Molecule Info | [5] | ||
| Serine/threonine-protein kinase mTOR (mTOR) | Molecule Info | |||
